In this work Zhu et colleagues release a high-quality metabolic reconstruction for the bacterium P. aeruginosa PAO1. The model has been validated and used to achieve an understanding of the adaptation to antibiotics. Given the global threat posed by MDR bacteria, I sincerely think systematic approaches (as this one) to identify potential weak points in troublesome strains are to be encouraged. Overall, the manuscript is well written and the conclusions are supported by the amount of data reported, and therefore should be published after some modifications. Below are reported my specific comments, divided for each section.
Introduction:
1) I would specify that the specific approach of applying gene expression constraints to obtain conditionspecific GEMs have been previously used for other MDR bacteria (e.g. A. baumannii doi:10.1038/s41598-017-03416-2).
Analyses:
1) lines 217-218: I would remove the sentence "Therefore, iPAO1 is a well-defined, metabolismdedicated model.", in that it is included in the definition of "metabolic reconstruction". The presence of genes associated to non-metabolic COG categories is, in my opinion, due to the presence of misannotated (for what concerns the COG categories) genes. Honestly, I wouldn't use the distribution of such categories as a measure of a model goodness, especially considering that some genes can be associated to multiple categories. All the other comparisons the authors made already highlighted how this reconstruction is the best one.
2) lines 253-258: "this is possibly due to the incorporation of new genes (30.5% increase compared to Opt208964; 27.2% increase compared to iPae1146) whose metabolic functions were previously misannotated." This is not clear... do the authors mean that the addition of new genes brought alternative routes to bypass previously essential gene deletion? This should be rephrased, and, if possible, the proposed explanation should be tested.
3) section "Elucidating the mechanisms of metabolic responses to polymyxin treatment":
In this section the authors use the previously presented model to describe the changes at a systems level of the metabolism in presence of polymixin treatment. I have two issues concerning this section: 3.1) The way the authors computed the flux distribution in presence of antibiotics. Given the nonoptimal state of such condition, I feel that MOMA is more appropriate. I suggest the authors to test this and compare the results with the current ones. 3.2) Although a description of the systemic changes induced by antibiotics is important, I think that the authors are missing an important point, that is the condition-specific essential genes. In my opinion this is very important and interesting, also considering that a selling point of the manuscript is that "iPAO1 offers an in silico platform for precision antimicrobial pharmacology therapy"
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